Elraglusib is aimed at treating pancreatic ductal adenocarcinoma. Credit: Jo Panuwat D/Shutterstock. Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European ...
Actuate Therapeutics (ACTU) announced that the European Medicines Agency, EMA, has granted Orphan Medicinal Product Designation, OMPD, to elraglusib, a novel GSK-3beta inhibitor, for the treatment ...
As a BDC, Ares Capital makes loans to middle-market companies, which generate between $10 million and $250 million in annual earnings before interest, taxes, depreciation, and amortization (EBITDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback